US Patent Issued to SUNGKWANG MEDICAL FOUNDATION on Oct. 14 for "Epigenetic biomarker composition for diagnosing Down syndrome, and use thereof" (South Korean Inventors)

ALEXANDRIA, Va., Oct. 21 -- United States Patent no. 12,442,041, issued on Oct. 14, was assigned to SUNGKWANG MEDICAL FOUNDATION (Seoul, South Korea).

"Epigenetic biomarker composition for diagnosing Down syndrome, and use thereof" was invented by Hyun Mee Ryu (Seongnam-si, South Korea) and Ji Hyae Lim (Seongnam-si, South Korea).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided are a composition for diagnosing Down syndrome, a kit including the composition, a diagnostic method, and a method of providing information for diagnosing Down syndrome, the composition including an agent for measuring a methylation level of any one gene selected from the group consisting of MXRA8, MIB2, KIF26B, SP5, ZIC4, ENPEP,...